Owlstone Medical Revenue and Competitors

Claim your profile

Location

$132.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Owlstone Medical's estimated annual revenue is currently $49.2M per year.(i)
  • Owlstone Medical received $50.0M in venture funding in October 2018.
  • 0
  • Owlstone Medical's total funding is $132.9M.

Employee Data

    00
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.7M376%N/AN/A
#2
$11.5M7419%N/AN/A
#3
$92.7M42715%$292MN/A
#4
$2.6M47219%$631.7MN/A
#5
$14.3M92-2%$81MN/A
#6
$1.2M278-6%$460.5MN/A
#7
$49.2M0N/A$132.9MN/A
#8
$12.1M78-17%N/AN/A
#9
$12.6M810%N/AN/A
#10
$233.6M94229%£994.6MN/A

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive early detection and precision medicine for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs. Owlstone Medical's Breath Biopsy® platform is a new diagnostic modality capable of detecting disease biomarkers in breath. The award winning ReCIVA Breath Sampler ensures reliable collection of breath samples. VOC (Volatile organic compound) biomarkers present in breath are analyzed with high sensitivity and selectivity using proven microchip chemical sensor technology (Field Asymmetric Ion Mobility Spectrometry, FAIMS). The Breath Biopsy platform has the potential to revolutionize early detection and precision medicine, with applications in cancer and a wide range of other conditions. Breath Biopsy enables disease to be detected earlier, when treatments are more effective and more lives can be saved. By identifying patients most likely to respond to a particular therapy, Breath Biopsy can also ensure that the right therapy is given to the right patient at the right time, helping to reduce healthcare costs. Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also provides Breath Biopsy products and services to academic, clinical and pharmaceutical partners who want to develop breath based biomarkers for their own applications. Owlstone Inc was founded in 2004 as a spin-out from the Engineering Department at the University of Cambridge, and is a profitable business selling FAIMS technology to military and industrial customers globally. Owlstone Medical was spun out from Owlstone Inc in 2016 to develop and commercialize FAIMS in medical applications. Owlstone Medical is headquartered in Cambridge, UK, with offices in London, UK.

keywords:N/A

$132.9M

Total Funding

N/A

Number of Employees

$49.2M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Owlstone Medical News

2022-04-19 - Minimally Invasive Biopsy Technologies Market Size And ...

... Veracyte, Inc., Thermo Fisher Scientific, NeoGenomics Laboratories, Inc., Abcodia Ltd., Adaptive Biotechnologies, Owlstone Medical Ltd.

2022-04-17 - Digital Olfactory technology Consumption Market Growth 2022 ...

... Market Growth 2022-2029| Key Players – Alpha MOS (France), Airsense Analytics (Germany), Odotech (Canada), Owlstone Medical (UK).

2022-04-17 - Farewell, Swabs? How a New COVID Breath Test Gives Results in 3 Minutes

... on breath tests, including Singapore's Breathonix, the UK's Owlstone Medical, Indonesia's GeNose C19 and Israel's Scentech Medical.

2021-09-08 - Coinbase takes its SEC battle to the public

This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content How this advanced tech will help machines see like humans From Telus International Few CEOs take their regulatory battles public to the Tw ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1941.5M0N/A$639M
#2
$64.9M0N/A$751.3M
#3
$9.5M0N/A$138M
#4
$5.9M0N/A$21.9M
#5
$8.8M0N/A$6.8M

Owlstone Medical Funding

DateAmountRoundLead InvestorsReference
2005-10-06$3.0MUndisclosedAdvance NanotechArticle
2006-09-08$1.2MUndisclosedArticle
2017-01-09$11.6MUndisclosedArticle
2017-03-28$23.5MUndisclosedAviva VenturesArticle
2018-03-06$15.0MUndisclosedHorizons VenturesArticle
2018-10-02$50.0MUndisclosedAviva VenturesArticle